Source: http://www.google.com/patents/US7622108?dq=6016038
Timestamp: 2017-12-14 01:11:57
Document Index: 43186793

Matched Legal Cases: ['§120', '§119', 'Application No. 60', 'Application No. 2005241008', 'Application No. 05', 'Application No. 05', 'Application No. 05', 'Application No. 200580012739']

Patent US7622108 - Multi-lineage progenitor cells - Google Patents
Fetal blood multi-lineage progenitor cells that are capable of a wide spectrum of transdifferentiation are described....http://www.google.com/patents/US7622108?utm_source=gb-gplus-sharePatent US7622108 - Multi-lineage progenitor cells
Publication number US7622108 B2
Application number US 11/208,873
Also published as US20060040392, WO2007025072A2, WO2007025072A3
Publication number 11208873, 208873, US 7622108 B2, US 7622108B2, US-B2-7622108, US7622108 B2, US7622108B2
Inventors Daniel P. Collins, Stacey L. Sprague, Barbara M. Tigges
Patent Citations (104), Non-Patent Citations (92), Referenced by (9), Classifications (18), Legal Events (7)
US 7622108 B2
This application is a continuation-in-part and claims benefit under 35 U.S.C. §120 of U.S. application Ser. No. 11/110,299, filed Apr. 20, 2005, which claims benefit under 35 U.S.C. §119(e) of U.S. Application No. 60/564,687, filed on Apr. 23, 2004, both of which are incorporated by reference herein in their entirety.
Anti-human glycophorin A (murine IgM monoclonal 0.1-15 mg/L
antibody, clone 2.2.2.E7) (preferably
Anti-CD15 (murine IgM monoclonal antibody, clone 0.1-15 mg/L
324.3.B9) (preferably
Anti-CD9 (murine IgM monoclonal antibody, clone 0.1-15 mg/L
8.10.E7) (preferably
Briefly, 50-150 ml of CPDA anti-coagulated umbilical cord blood (<48 hours old) was gently mixed with an equal volume of cell separation composition described in Table 3 for 30 minutes. After mixing was complete, the container holding the blood/cell separation composition mixture was placed in an upright position and the contents allowed to settle by normal 1×g gravity for 30 minutes. After settling was complete, the non-agglutinated cells were collected from the supernatant. The cells were recovered from the supernatant by centrifugation then washed with PBS. Cells were resuspended in complete MSCGM™ (Mesenchymal stem cell growth medium, catalog # PT-3001, Cambrex, Walkersville, Md.) and adjusted to 2-9×106 cells/ml with complete MSCGM™. Cells were plated in a standard plastic tissue culture flask (e.g., Corning), chambered slide, or other culture device and allowed to incubate overnight at 37° C. in a 5% CO2 humidified atmosphere. All subsequent incubations were performed at 37° C. in a 5% CO2 humidified atmosphere unless otherwise noted. MLPC attached to the plastic during this initial incubation. Non-adherent cells (T-cells, NK-cells and CD34+ hematopoietic stem cells) were removed by vigorous washing of the flask or well with complete MSCGM™.
A population of MLPC and clonal cell line UM081704-1-E8 each were cultured in complete MSCGM™ and grown under logarithmic growth conditions outlined above. Cells were harvested by treatment with PBS+0.1% EGTA and replated at 5×103 to 2×104/ml in complete MSCGM™. The cells were allowed to adhere overnight and then the medium was replaced with Osteogenic Differentiation Medium (catalog # PT-3002, Cambrex) consisting of complete MSCGM™ supplemented with dexamethasone, L-glutamine, ascorbate, and β-glycerophosphate. Cells were cultured at 37° C. in a 5% CO2 atmosphere and fed every 3-4 days for 2-3 weeks. Deposition of calcium crystals was demonstrated by using a modification of the Alizarin red procedure and observing red staining of calcium mineralization by phase contrast and fluorescent microscopy.
Bone marrow derived hMSC (Cambrex), cord blood MLPC, and MLPC clonal cell line were grown under logarithmic growth conditions described above. Cells were harvested as described above and replated at 0.8×104 cells per chamber in 4-chamber slides that were pre-coated with poly-D-lysine and laminin (BD Biosciences Discovery Labware, catalog #354688) in 0.5 mL of NPMM™ (catalog #CC-3209, Cambrex) containing huFGF-basic, huEGF, brain-derived neurotrophic factor, neural survival factor-1, fibroblast growth factor-4 (20 ng/mL), and 200 mM GlutaMax I Supplement (catalog #35050-061, Invitrogen, Carlsbad, Calif.). The medium was changed every 2-3 days for 21 days. Neurospheres developed after 4 to 20 days. Transformation of MLPC to neural lineage was confirmed by positive staining for nestin (monoclonal anti-human nestin antibody, MAB1259, clone 196908, R&D Systems), class III beta-tubulin (tubulin b-4) (monoclonal anti-neuron-specific class III beta-tubulin antibody, MAB 1195, Clone TuJ-1, R&D Systems), glial fibrillary acidic protein (GFAP) (monoclonal anti-human GFAP, HG2b-GF5, clone GF5, Advanced immunochemical, Inc.), and galactocerebroside (GalC) (mouse anti-human GalC monoclonal antibody MAB342, clone mGalC, Chemicon).
Example 12 Comparative Gene Expression of MLPC
In order to determine the relationship between MLPC and various other cell types at various stages of lineage commitment, the relative expression of 942 genes associated with “stemness” and differentiating capacity was assessed by high definition microarray. The phenotype of MLPC (E8 clone, passage 8, see Example 5) was compared to human umbilical cord mononuclear cells (MNC), PrepaCyte®-MLPC isolated cord blood cells, CD133+ positively selected cord blood progenitor cells, lineage negative cord blood cells, and bone marrow-derived mesenchymal stem cells (MSC, Cambrex, Walkersville, Md.). The MNC were isolated by density gradient centrifugation method on Ficoll. Cells were mature terminally differentiated lymphocytes and monocytes with some minor contamination with platelets and granulocytes. The PrepaCyte isolated cells were human umbilical cord blood cells isolated by PrepaCyte-MLPC method. Cells were mainly lymphocytes, hematopoietic stem cells, and MLPC with some minor contamination with monocytes, granulocytes, and platelets. CD133+ selected cells were human umbilical cord blood cells separated by Ficoll density gradient separation then positively selected using anti-CD133 coated paramagnetic particles (Miltenyi). These cells are consistent with hematopoietic stem cells. Lineage Negative cells were isolated from human umbilical cord blood cells by Ficoll density gradient separation then negatively selected by depletion with anti-CD45, anti-CD7, and anti-glycophorin A-coated paramagnetic particles. These cells have been demonstrated to have some multi-lineage differentiating capacity. See, Forrz et al., Stem Cells, 22(1):100-108 (2004). MSC were purchased from Cambrex (catalog # PT-2501).
genno. Description
11328 TDGF1-TDGF3_2_HUMAN: (TDGF1 OR CRIPTO) TERATOCARCINOMA-DERIVED B
11644 ACVR2B: (ACVR2B) ACTIVIN RECEPTOR TYPE IIB PRECURSOR (EC 2.7.1.—) (ACTR-IIB). A B
11647 ACVRL1: (ACVRL1 OR ACVRLK1 OR ALK1) SERINE/THREONINE-PROTEIN KINASE A B
11689 BMPR1B: (BMPR1B OR ACVRLK6) BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE A B
11767 EPHB2: (EPHB2 OR EPTH3 OR ERK OR DRT OR HEK5) EPHRIN TYPE-B RECEPTOR 2 A B
12034 PRKCZ: (PRKCZ OR PKC2) PROTEIN KINASE C, ZETA TYPE (EC 2.7.1.—) (NPKC-ZETA). A B
12452 CD45_EX10-11: (PTPRC OR CD45) LEUKOCYTE COMMON ANTIGEN PRECURSOR (EC B
12920 PRKCQ: (PRKCQ OR PRKCT) PROTEIN KINASE C, THETA TYPE (EC 2.7.1.—) (NPKC- A B
139 MAPK3: (MAPK3 OR PRKM3 OR ERK1) MITOGEN-ACTIVATED PROTEIN KINASE 3 (EC A B
14773 AKT2: (AKT2) RAC-BETA SERINE/THREONINE PROTEIN KINASE (EC 2.7.1.—) (RAC-PK- A B
1499 PRKCB_2: (PRKCB1 OR PRKCB OR PKCB) PROTEIN KINASE C, BETA TYPE (EC 2.7.1.37) A B
15194 PAK1: (PAK1) SERINE/THREONINE-PROTEIN KINASE PAK 1 (EC 2.7.1.—) (P21- A B
15492 MAP3K3: (MAP3K3 OR MAPKKK3 OR MEKK3) MITOGEN-ACTIVATED PROTEIN A B
1915 CSK: (CSK) TYROSINE-PROTEIN KINASE CSK (EC 2.7.1.112) (C-SRC KINASE) (PROTEIN- A B
1953 PIK3CG: (PIK3CG) PHOSPHATIDYLINOSITOL 3-KINASE CATALYTIC SUBUNIT, B
322 KIT: (KIT OR SL) MAST/STEM CELL GROWTH FACTOR RECEPTOR PRECURSOR (EC A B
357 PDGFRB: (PDGFRB OR PDGFR) BETA PLATELET-DERIVED GROWTH FACTOR A B
4042 IKKA: (IKK ALPHA OR CHUK) INHIBITOR OF NUCLEAR FACTOR KAPPA-B KINASE A B
5042 PTEN1-PTEN2: (PTEN OR MMAC1 OR TEP1) PROTEIN-TYROSINE PHOSPHATASE PTEN B
5209 FGFR2: (FGFR2 OR ECT1 OR BEK) FIBROBLAST GROWTH FACTOR RECEPTOR 2 A B
5225 NTRK3: (NTRK3 OR TRKC) NT-3 GROWTH FACTOR RECEPTOR PRECURSOR (EC A B
7088 CDC25B: (CDC25B OR CDC25HU2) M-PHASE INDUCER PHOSPHATASE 2 (EC 3.1.3.48). B
9099 FGFR3: (FGFR3 OR JTK4) FIBROBLAST GROWTH FACTOR RECEPTOR 3 PRECURSOR A B
10934 CHEK1: (CHEK1 OR CHK1) SERINE/THREONINE-PROTEIN KINASE CHK1 (EC A B C H I
10937 CHEK2: (CHEK2 OR CHK2) SERINE/THREONINE-PROTEIN KINASE CHK2 (EC A C I
10985 HMGB2: (HMGB2 OR HMG2) HIGH MOBILITY GROUP PROTEIN HMG2 (HMG-2). A
118 CCNB2: (CCNB2) CYCLIN B2 G2/MITOTIC SPECIFIC CYCLIN B2. A B C H
13004 ELAVL2: (ELAVL2 OR HUB) ELAV-LIKE PROTEIN 2 (HU-ANTIGEN B) (HUB) A
138 CCNE2: (CCNE2) G1/S-SPECIFIC CYCLIN E2. A C H I
14809 BUB1: (BUB1 OR BUB1L) MITOTIC CHECKPOINT SERINE/THREONINE- A B C F H I S
17848 DNMT1: (DNMT1 OR DNMT OR AIM) DNA (CYTOSINE-5)- A
18164 HMGIY: (HMGIY OR HMGA1 OR HMGI) HIGH MOBILITY GROUP PROTEIN A
22039 GPS1_3PRIME: (GPS1 OR COPS1) COP9 SIGNALOSOME COMPLEX SUBUNIT 1 A
22663 HNRPA1: (HNRPA1) HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN A1 A
2429 BAMACAN: (BAM OR SMCD OR HCAP OR CSPG6 OR SMC3 OR SMC3L1 OR B H S
24938 C20ORF1: (C20ORF1 OR C20ORF2 OR DIL2 OR TPX2) RESTRICTED EXPRESSION A B H S
26268 VAP-A: (VAP-A OR VAP33) VAMP-ASSOCIATED PROTEIN A (VAPA). S
26951 NME2: (NME2 OR NM23B) NUCLEOSIDE DIPHOSPHATE KINASE B (EC 2.7.4.6) L P
27251 PTTG_HUMAN: (PTTG) PITUITARY TUMOR TRANSFORMING GENE, A B H
27741 MAD2L1: (MAD2L1 OR MAD2 OR MAD2A) MITOTIC SPINDLE ASSEMBLY A B C F H I S
28320 KPNA2: (KPNA2 OR RCH1 OR SRP1) IMPORTIN ALPHA-2 SUBUNIT B H
28475 LAPTM4B: (LAPTM4B OR LAPTM4BETA OR DKFZP586E1124) LYSOSOMAL- P
3018 HPRT: (HPRT1 OR HPRT) HYPOXANTHINE-GUANINE A L
30231 SNRPF: (SNRPF OR PBSCF) SMALL NUCLEAR RIBONUCLEOPROTEIN F A
30969 BUB1B: (BUB1B OR MAD3L OR BUBR1) MITOTIC CHECKPOINT A B C F H I
30972 BUB3: (BUB3) MITOTIC CHECKPOINT PROTEIN BUB3. A B C F H I
31008 DTYMK: (DTYMK OR TYMK OR TMPK OR CDC8) THYMIDYLATE KINASE (EC L P
31099 MAD2L2: (MAD2L2 OR MAD2B OR REV7) MITOTIC SPINDLE ASSEMBLY A B C F H I
31129 PPP2R1B_1: (PPP2R1B) SERINE/THREONINE PROTEIN PHOSPHATASE 2A, 65 S
32488 NPM1: (NPM1 OR NPM) NUCLEOPHOSMIN (NPM) (NUCLEOLAR A B S
32694 IMPDH2: (IMPDH2 OR IMPD2) INOSINE-5′-MONOPHOSPHATE L P
32700 KIAA1573: (KIAA1573) HYPOTHETICAL PROTEIN KIAA1573 (B430218L07RIK)
32703 KIF4A: (KIF4A OR KIF4) CHROMOSOME-ASSOCIATED KINESIN KIF4A A S
32706 LIN-28: (LIN28 OR LIN-28) HYPOTHETICAL PROTEIN FLJ12457 (RNA-BINDING PROTEIN
32712 MTHFD1: (MTHFD1 OR MTHFD OR MTHFC) C-1-TETRAHYDROFOLATE L
32716 PPAT: (PPAT OR GPAT) AMIDOPHOSPHORIBOSYLTRANSFERASE PRECURSOR A L P
49 TUBA_HUMAN: (TUBA3) (TUBA6) TUBULIN ALPHA-UBIQUITOUS CHAIN S
5036 MYB: (MYB) MYB PROTO-ONCOGENE PROTEIN (C-MYB). H
5131 CDK1: (CDC2) CELL DIVISION CONTROL PROTEIN 2 HOMOLOG (EC 2.7.1.—) A B C F H I
5137 CDK4: (CDK4) CELL DIVISION PROTEIN KINASE 4 (EC 2.7.1.—) (CYCLIN- A C H
55 TUBB1-TUBB5_HUMAN: (TUBB1) TUBULIN BETA-1 CHAIN. (TUBB5) TUBULIN BETA-5 A S
7091 CDC25C: (CDC25C) M-PHASE INDUCER PHOSPHATASE 3 (EC 3.1.3.48). A B C F H
7996 TK1: (TK1) THYMIDINE KINASE, CYTOSOLIC (EC 2.7.1.21). P
91 P53: (TP53 OR P53) CELLULAR TUMOR ANTIGEN P53 (TUMOR SUPPRESSOR A C I
9386 RBL1: (RBL1) RETINOBLASTOMA-LIKE PROTEIN 1 (107 KDA A C
11204 KRT8: (KRT8 OR CYK8) KERATIN, TYPE II CYTOSKELETAL 8 (CYTOKERATIN 8) (K8) E
11704 CD44_EX13-15_HUMAN: (CD44 OR LHR) CD44 ANTIGEN PRECURSOR (PHAGOCYTIC D
11710 CD44_EX7-9_HUMAN: (CD44 OR LHR) CD44 ANTIGEN PRECURSOR (PHAGOCYTIC D
12710 CD44_EX8-10_HUMAN: (CD44 OR LHR) CD44 ANTIGEN PRECURSOR (PHAGOCYTIC D
1294 CTGF: (CTGF OR HCS24) CONNECTIVE TISSUE GROWTH FACTOR PRECURSOR D
1447 SLIT1: (SLIT1 or KIAA0813 or MEGF4) Slit homolog 1 protein precursor (Slit-1) (Multiple C D
16675 MYL4: (MYL4 OR MLC1) MYOSIN LIGHT CHAIN 1, EMBRYONIC MUSCLE/ATRIAL E
1691 ACTB: (ACTB) BETA1, CYTOPLASMIC (BETA-ACTIN) ACTIN, CYTOPLASMIC 1. E
21478 VIM: (VIM) VIMENTIN. E
2260 COL1A1: (COL1A1) COLLAGEN ALPHA 1(I) CHAIN PRECURSOR. B E
2264 COL11A1: (COL11A1) COLLAGEN ALPHA 1(XI) CHAIN PRECURSOR. B C D E
2275 COL15A1: (COL15A1) COLLAGEN ALPHA 1(XV) CHAIN PRECURSOR. B C D E
2277 COL16A1: (COL16A1) COLLAGEN ALPHA 1(XVI) CHAIN PRECURSOR. B C D E
2289 COL4A1: (COL4A1) COLLAGEN ALPHA 1(IV) CHAIN PRECURSOR (ARRESTEN). B E
2295 COL7A1: (COL7A1) COLLAGEN ALPHA 1(VII) CHAIN PRECURSOR (LONG-CHAIN B D E
2326 ITGA8: (ITGA8) INTEGRIN ALPHA-8 (INTEGRINA8). B D
2332 ITGB6: (ITGB6) INTEGRIN BETA-6 PRECURSOR (INTEGRINB6). B D
23322 CLDN1: (CLDN1 OR CLD1 OR SEMP1) CLAUDIN-1 (SENESCENCE-ASSOCIATED D E
2338 PAI1: (SERPINE1 OR PAI1 OR PLANH1) PLASMINOGEN ACTIVATOR INHIBITOR-1 B
2352 TPA: (PLAT) TISSUE-TYPE PLASMINOGEN ACTIVATOR PRECURSOR (EC 3.4.21.68) B
2362 LAMA2: (LAMA2 OR LAMM) LAMININ ALPHA-2 CHAIN PRECURSOR (LAMININ M B C D E
2364 LAMA3: (LAMA3) LAMININ ALPHA-3 CHAIN PRECURSOR (EPILIGRIN 170 KDA B C D E
2366 LAMA4: (LAMA4) LAMININ ALPHA-4 CHAIN PRECURSOR. B C D E
2423 AGGRECAN1: (AGC1 OR CSPG1 OR AGC) AGGRECAN CORE PROTEIN PRECURSOR B D E
2433 BMP1_1: (BMP1 OR PCP-3) BONE MORPHOGENETIC PROTEIN 1 PRECURSOR (EC B
2453 FN1: (FN1 OR FN) FIBRONECTIN PRECURSOR (FN) (COLD-INSOLUBLE GLOBULIN) B D E
2491 MMP12: (MMP12 OR HME) MACROPHAGE METALLOELASTASE PRECURSOR (EC B
2501 MMP2: (MMP2 OR CLG4A) 72 KDA TYPE IV COLLAGENASE PRECURSOR (EC B
2555 THBS1: (THBS1 OR TSP1 OR TSP) THROMBOSPONDIN 1 PRECURSOR B C D E
30689 FN1_REPEAT-B: (FN1 OR FN) FIBRONECTIN PRECURSOR (FN) (COLD-INSOLUBLE B D E
365 CDH5: (CDH5) VASCULAR ENDOTHELIAL-CADHERIN PRECURSOR (VE-CADHERIN) D
3676 FOXG1A-FOXG1B: (FOXG1B OR FKHL1) FORKHEAD PROTEIN G1B (FORKHEAD- D
387 ALCAM: (ALCAM) CD166 ANTIGEN PRECURSOR (ACTIVATED LEUKOCYTE-CELL D
3919 MAP-2: (MAP2) MICROTUBULE-ASSOCIATED PROTEIN 2 (MAP2B) [CONTAINS: E
401 ITGB3: (ITGB3 OR GP3A) INTEGRIN BETA-3 PRECURSOR (PLATELET MEMBRANE B D
549 ITGA1_2: (ITGA1) INTEGRIN ALPHA-1 (LAMININ AND COLLAGEN RECEPTOR) (VLA- B D
573 CD9: (CD9 OR MIC3) CD9 ANTIGEN (P24) (LEUKOCYTE ANTIGEN MIC3) (MOTILITY- D
7939 RHOA: (ARHA OR ARH12 OR RHOA OR RHO12) TRANSFORMING PROTEIN RHOA D
11181 KRT18: (KRT18 OR CYK18) KERATIN, TYPE I CYTOSKELETAL 18 C
11204 KRT8: (KRT8 OR CYK8) KERATIN, TYPE II CYTOSKELETAL 8 (CYTOKERATIN C
11334 TPM1: (TPM1 OR TPMA OR TMSA) TROPOMYOSIN ALPHA CHAIN. C
11641 ACVR2: (ACVR2) ACTIVIN RECEPTOR TYPE II PRECURSOR (EC 2.7.1.—) (ACTR- E
11683 BMP15: (BMP15 OR GDF9B) BONE MORPHOGENETIC PROTEIN 15 PRECURSOR E R
11686 BMPR1A: (BMPR1A OR ACVRLK3) BONE MORPHOGENETIC PROTEIN E I
11804 GATA4_HUMAN: (GATA4) TRANSCRIPTION FACTOR GATA-4 (GATA BINDING
12091 SHH: (SHH) SONIC HEDGEHOG PROTEIN PRECURSOR (SHH) (HHG-1). E I R
1210 FZD4: (FZD4) WNT RECEPTOR FRIZZLED-4, FRIZZLED 4 PRECURSOR E
12917 PRKCM: (PRKCM) PROTEIN KINASE C, MU TYPE (EC 2.7.1.—) (NPKC-MU). E
1294 CTGF: (CTGF OR HCS24) CONNECTIVE TISSUE GROWTH FACTOR PRECURSOR A E I R
13106 NTF3: (NTF3) NEUROTROPHIN-3 PRECURSOR (NT-3) (NEUROTROPHIC E I R
13234 BDNF: (BDNF) BRAIN-DERIVED NEUROTROPHIC FACTOR PRECURSOR E R
1350 PDGB: (PDGFB OR C-SIS OR PDGF2 OR SIS) PLATELET-DERIVED GROWTH E R
143 MAPK6: (MAPK6 OR PRKM6 OR ERK3) MITOGEN-ACTIVATED PROTEIN L
1436 VEGF_1: (VEGF OR VEGFA) VASCULAR ENDOTHELIAL GROWTH FACTOR A E I R
1442 WISP3: (WISP3 OR CCN6 OR DJ142L7.3 OR LIBC) WNT1 INDUCIBLE SIGNALING E R
1465 VEGFD: (FIGF OR VEGF-D) VASCULAR ENDOTHELIAL GROWTH FACTOR D (C- E R
14749 VEGF_2: (VEGF OR VEGFA) VASCULAR ENDOTHELIAL GROWTH FACTOR A E I R
15116 EPHB4: (EPHB4 OR HTK) EPHRIN TYPE-B RECEPTOR 4 PRECURSOR (EC E
1691 ACTB: (ACTB) BETA1, CYTOPLASMIC (BETA-ACTIN) ACTIN, CYTOPLASMIC 1. C L
1710 MAPT: (MAPT OR MTBT1 OR TAU) MICROTUBULE-ASSOCIATED PROTEIN C
18385 IGFBP2: (IGFBP2 OR BP2) INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN E R
20532 SEMA3B: (SEMA3B OR SEMA5) SEMAPHORIN 3B PRECURSOR (SEMAPHORIN E
20586 SEMA4C: (SEMA4C OR KIAA1739) SEMAPHORIN 4C PRECURSOR (SEMAI) E
20616 ASPIC1: (ASPIC1 OR CEP-68) ASPIC PRECURSOR (CHONDROCYTE EXPRESSED D
2108 INHBA: (INHBA) INHIBIN BETA A CHAIN PRECURSOR (ACTIVIN BETA-A E I R
21481 VTN: (VTN) VITRONECTIN PRECURSOR (SERUM SPREADING FACTOR) (S- C E
2183 VEGC: (VEGFC) VASCULAR ENDOTHELIAL GROWTH FACTOR C PRECURSOR E R
2260 COL1A1: (COL1A1) COLLAGEN ALPHA 1(I) CHAIN PRECURSOR. A C D E I J
2264 COL11A1: (COL11A1) COLLAGEN ALPHA 1(XI) CHAIN PRECURSOR. A C D E I J
2266 COL12A1: (COL12A1) COLLAGEN ALPHA 1(XII) CHAIN PRECURSOR. A C D E J
2271 COL14A1: (COL14A1) EXTRACELLULAR MATRIX PROTEIN COLLAGEN TYPE C D J
2275 COL15A1: (COL15A1) COLLAGEN ALPHA 1(XV) CHAIN PRECURSOR. A C D E J
2277 COL16A1: (COL16A1) COLLAGEN ALPHA 1(XVI) CHAIN PRECURSOR. A C D E J
2289 COL4A1: (COL4A1) COLLAGEN ALPHA 1(IV) CHAIN PRECURSOR (ARRESTEN). A C D E J
2293 COL6A1: (COL6A1) COLLAGEN (VI) ALPHA-1 CHAIN (FRAGMENT) COLLAGEN A C D E J
2295 COL7A1: (COL7A1) COLLAGEN ALPHA 1(VII) CHAIN PRECURSOR (LONG- A C D E I J
2297 COL8A1: (COL8A1) COLLAGEN ALPHA 1(VIII) CHAIN PRECURSOR A C D E J
2301 COL1A2: (COL1A2) COLLAGEN ALPHA 2(I) CHAIN PRECURSOR. A C D E J
2307 COL5A2: (COL5A2) COLLAGEN ALPHA 2(V) CHAIN PRECURSOR. A C D E J
2309 COL6A2_1: (COL6A2) COLLAGEN ALPHA 2(VI) CHAIN PRECURSOR. A C D E J
2315 COL4A3_1: (COL4A3) COLLAGEN ALPHA 3(IV) CHAIN PRECURSOR. A C D E J
2324 ITGA7: (ITGA7) INTEGRIN ALPHA-7 (INTEGRIN ALPHA 7 CHAIN) (INTEGRIN D E
2326 ITGA8: (ITGA8) INTEGRIN ALPHA-8 (INTEGRINA8). D
2330 ITGB5: (ITGB5) INTEGRIN BETA-5 PRECURSOR (INTEGRINB5). D E
2332 ITGB6: (ITGB6) INTEGRIN BETA-6 PRECURSOR (INTEGRINB6). D
2336 ITGB8: (ITGB8) INTEGRIN BETA-8 PRECURSOR. D
23367 CLDN6: (CLDN6) CLAUDIN-6 (SKULLIN 2). C
2338 PAI1: (SERPINE1 OR PAI1 OR PLANH1) PLASMINOGEN ACTIVATOR D E
2344 TIMP1: (TIMP1 OR TIMP OR CLGI) METALLOPROTEINASE INHIBITOR 1 A D E
2348 TIMP3: (TIMP3) METALLOPROTEINASE INHIBITOR 3 PRECURSOR (TIMP-3) A D E
2352 TPA: (PLAT) TISSUE-TYPE PLASMINOGEN ACTIVATOR PRECURSOR (EC D E
2356 BMP7: (BMP7 OR BMP-7 OR OP1) BONE MORPHOGENETIC PROTEIN 7 D E R
2360 LAMA1: (LAMA1 OR LAMA) LAMININ ALPHA-1 CHAIN PRECURSOR (LAMININ A C D E I K
2362 LAMA2: (LAMA2 OR LAMM) LAMININ ALPHA-2 CHAIN PRECURSOR (LAMININ A C D E K
2366 LAMA4: (LAMA4) LAMININ ALPHA-4 CHAIN PRECURSOR. A C D E K
2368 LAMA5: (KIAA0533 OR LAMA5) KIAA0533 PROTEIN (LAMININ ALPHA 5 A C D E K
2370 LAMB1: (LAMB1) LAMININ BETA-1 CHAIN PRECURSOR (LAMININ B1 CHAIN). A C D E K
2375 LAMB3: (LAMB3) LAMININ BETA-3 CHAIN PRECURSOR (LAMININ B1K A C D E I K
2377 LAMG1: (LAMC1 OR LAMB2) LAMININ GAMMA-1 CHAIN PRECURSOR A C D E I K
2423 AGGRECAN1: (AGC1 OR CSPG1 OR AGC) AGGRECAN CORE PROTEIN A C D E I R
2433 BMP1_1: (BMP1 OR PCP-3) BONE MORPHOGENETIC PROTEIN 1 PRECURSOR D E I
2453 FN1: (FN1 OR FN) FIBRONECTIN PRECURSOR (FN) (COLD-INSOLUBLE A C D E R
2473 LUMICAN: (LDC) LUMICAN PRECURSOR (LUM) (KERATAN SULFATE A C D E
2489 MMP11: (MMP11 OR STMY3) STROMELYSIN-3 PRECURSOR (EC 3.4.24.—) A D E
2493 MMP13: (MMP13) COLLAGENASE 3 PRECURSOR (EC 3.4.24.—) (MATRIX A D E J
2501 MMP2: (MMP2 OR CLG4A) 72 KDA TYPE IV COLLAGENASE PRECURSOR (EC A D E
2527 DCN_1: (DCN) BONE PROTEOGLYCAN II PRECURSOR (PG-S2) (DECORIN) A C D E
2531 RYUDOCAN: (SDC4) SYNDECAN-4 PRECURSOR (AMPHIGLYCAN) (SYND4) C D E
2541 TNC: (TNC OR HXB) TENASCIN PRECURSOR (TN) (HEXABRACHION) A C D E
25417 KCNK4: (KCNK4 OR TRAAK) POTASSIUM CHANNEL SUBFAMILY K MEMBER 4 E
2549 THBS2: (THBS2 OR TSP2) THROMBOSPONDIN 2 PRECURSOR A C D E
2555 THBS1: (THBS1 OR TSP1 OR TSP) THROMBOSPONDIN 1 PRECURSOR C D E
2557 COMP: (COMP) CARTILAGE OLIGOMERIC MATRIX PROTEIN PRECURSOR A C D E
2560 MMP19: (MMP19 OR MMP18 OR RASI) MATRIX METALLOPROTEINASE-19 A D E
26175 GPC4: (GPC4) GLYPICAN-4 PRECURSOR (K-GLYPICAN). A E
27246 PTN: (PTN OR NEGF1 OR HBNF1) PLEIOTROPHIN PRECURSOR (PTN) A E R
27501 ALPL: (ALPL) ALKALINE PHOSPHATASE, TISSUE-NONSPECIFIC ISOZYME E
28921 RELN: (RELN OR RL) REELIN PRECURSOR (EC 3.4.21.—) (REELER PROTEIN). A E R
28937 TUBB4_HUMAN: (TUBB4) TUBULIN BETA-4 CHAIN (TUBULIN BETA-III). C
29310 SNAI2: (SNAI2 OR SLUG OR SLUGH) ZINC FINGER PROTEIN SLUG (NEURAL I L
2936 IL6: (IL6 OR IFNB2 OR IL-6) INTERLEUKIN-6 PRECURSOR (IL-6) (B-CELL E R
30327 ACTC: (ACTC OR ACTC1) ACTIN, ALPHA CARDIAC. C
3058 PRDC: (PRDC) PRDC (FLJ21195). R
30615 SDF2: (SDF2) STROMAL CELL-DERIVED FACTOR 2 PRECURSOR (SDF-2). E R
30624 BMP11: (GDF11 OR BMP11) GROWTH/DIFFERENTIATION FACTOR 11 E I R
30686 FN1_REPEAT-A: (FN1 OR FN) FIBRONECTIN PRECURSOR (FN) (COLD- A C D E R
30689 FN1_REPEAT-B: (FN1 OR FN) FIBRONECTIN PRECURSOR (FN) (COLD- A C D E R
309 ENG: (ENG OR END) ENDOGLIN PRECURSOR (CD105 ANTIGEN) (CELL E
30999 CTNNA2: (CTNNA2 OR CAPR) ALPHA-2 CATENIN (ALPHA-CATENIN RELATED C L
31066 HSCDGF: (HSCDGF OR PDGFC) SECRETORY GROWTH FACTOR-LIKE PROTEIN R
311 VCAM1: (VCAM1 OR L1CAM OR VCAM-1) VASCULAR CELL ADHESION E
31153 SNAI1: (SNAI1 OR SNAH) ZINC FINGER PROTEIN SNAI1 (SNAIL PROTEIN I L
343 IL6ST: (IL6ST) INTERLEUKIN-6 RECEPTOR BETA CHAIN PRECURSOR (IL-6R- E
355 PDGFRA: (PDGFRA) ALPHA PLATELET-DERIVED GROWTH FACTOR E
4528 CXCL12: (CXCL12 OR SDF1) STROMAL CELL-DERIVED FACTOR 1 PRECURSOR E R
4683 BFGFR_1_HUMAN: (FGFR1 OR FLG OR FGFBR OR FLT2) BASIC FIBROBLAST E L
4693 EGFR-LONG: (EGFR OR ERBB1) EPIDERMAL GROWTH FACTOR RECEPTOR L
4695 FN1_EIIIA: (FN1 OR FN) FIBRONECTIN PRECURSOR (FIBRONECTIN EIILA A C D E R
4699 EDN1: (EDN1) ENDOTHELIN-1 PRECURSOR (ET-1). E
47 ACTA2: (ACTA2 OR ACTSA OR ACTVS) AORTIC SMOOTH MUSCLE (ALPHA- C
4701 EDN2: (EDN2) ENDOTHELIN-2 PRECURSOR (ET-2) (VASOACTIVE INTESTINAL E
4705 GFAP_1_HUMAN: (GFAP) GLIAL FIBRILLARY ACIDIC PROTEIN, ASTROCYTE C
4715 SERPINH1-SERPINH2: (SERPINH1 OR CBP1 OR HSP47) HEAT SHOCK PROTEIN D E
4727 IGF1R: (IGF1R) INSULIN-LIKE GROWTH FACTOR I RECEPTOR PRECURSOR (EC E L
4747 M6PR_HUMAN: (IGF2R OR MPRI) CATION-INDEPENDENT MANNOSE-6- E
4767 SMAD3_HUMAN: (MADH3 OR SMAD3 OR MAD33) MOTHERS AGAINST L
499 ITGB1: (ITGB1 OR FNRB) INTEGRIN BETA-1 PRECURSOR (FIBRONECTIN D E
4990 NRG1: (NRG1 OR HGL OR NDF OR HRGA OR GGF OR SMDF) PRO- E
5056 IGF1: (IGF-I OR IGF1) INSULIN-LIKE GROWTH FACTOR I PRECURSOR E R
5149 CDKN2A_1_HUMAN: (CDKN2A OR CDKN2) CYCLIN-DEPENDENT KINASE 4 I
5177 FGF1: (FGF1 OR FGFA) HEPARIN-BINDING GROWTH FACTOR 1 PRECURSOR E R
5199 FGF5: (FGF5) FIBROBLAST GROWTH FACTOR-5 PRECURSOR (FGF-5) (HBGF-5). E R
5201 FGF6: (FGF6 OR HST2) FIBROBLAST GROWTH FACTOR-6 PRECURSOR (FGF-6) E R
5203 FGF7: (FGF7 OR KGF) KERATINOCYTE GROWTH FACTOR PRECURSOR (KGF) E I R
5211 IGF2_1: (IGF2) INSULIN-LIKE GROWTH FACTOR II PRECURSOR (IGF-II) E R
5213 LEPR: (OBR OR LEPR OR DB OR FA) LEPTIN RECEPTOR PRECURSOR (LEP-R) E R
5219 NGFB: (NGFB) BETA-NERVE GROWTH FACTOR PRECURSOR (BETA-NGF). E R
5231 VGR3: (FLT4) VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 3 E
5233 CDH1: (CDH1 OR UVO OR CDHE) EPITHELIAL-CADHERIN PRECURSOR (E- E L
5434 EDN3: (EDN3) ENDOTHELIN-3 PRECURSOR (ET-3). E R
5456 FGF2_1: (FGF2 OR FGFB) HEPARIN-BINDING GROWTH FACTOR 2 PRECURSOR E R
549 ITGA1_2: (ITGA1) INTEGRIN ALPHA-1 (LAMININ AND COLLAGEN RECEPTOR) D
5498 VLDLR: (VLDLR OR LDVR) VERY LOW-DENSITY LIPOPROTEIN RECEPTOR E
556 ITGA5: (ITGA5 OR FNRA) INTEGRIN ALPHA-5 PRECURSOR (FIBRONECTIN D E
6204 PCK2: (PCK2 OR PEPCK2) PHOSPHOENOLPYRUVATE CARBOXYKINASE,
6515 AMBP: (AMBP OR ITIL OR HCP) AMBP PROTEIN PRECURSOR [CONTAINS: E R
7010 TTR: (TTR OR PALB) TRANSTHYRETIN PRECURSOR (PREALBUMIN) (TBPA) E R
7804 KRT14: (KRT14) KERATIN, TYPE I CYTOSKELETAL 14 (CYTOKERATIN 14) C I
7807 KRT17: (KRT17) KERATIN, TYPE I CYTOSKELETAL 17 (CYTOKERATIN 17) C I
7837 NCAD: (CDH2 OR CDHN OR NCAD) NEURAL-CADHERIN PRECURSOR (N- A E
7939 RHOA: (ARHA OR ARH12 OR RHOA OR RHO12) TRANSFORMING PROTEIN L
8071 CTNNA1: (CTNNA1) ALPHA-1 CATENIN (CADHERIN-ASSOCIATED PROTEIN) C L
9037 HJ1: (JAG1) JAGGED 1 PRECURSOR (JAGGED1) (HJ1) NOTCH LIGAND JAGGED E
9060 ACTG2: (ACTG2 OR ACTA3 OR ACTSG) ACTIN, GAMMA-ENTERIC SMOOTH C
9102 FLN1: (FLNA OR FLN1 OR FLN) FILAMIN A (ALPHA-FILAMIN) (FILAMIN 1) C
9132 MYH11: (MYH11) MYOSIN HEAVY CHAIN, SMOOTH MUSCLE ISOFORM C
9314 CRABP2: (CRABP2) RETINOIC ACID-BINDING PROTEIN II, CELLULAR (CRABP- I
9407 SOX9: (SOX9) TRANSCRIPTION FACTOR SOX-9. I
9443 WNT3: (WNT3 OR WNT-3 OR INT4) WNT-3 PROTO-ONCOGENE PROTEIN A E R
9452 WNT5A: (WNT5A OR WNT-5A) WNT-5A PROTEIN PRECURSOR. E R
11074 TERT: (TERT OR TRT OR EST2 OR TCS1) TELOMERASE REVERSE B
11701 CD44_EX16-20_HUMAN: (CD44 OR LHR) CD44 ANTIGEN PRECURSOR A C J
11707 CD44_EX3-5_HUMAN: (CD44 OR LHR) CD44 ANTIGEN PRECURSOR (PHAGOCYTIC A C J
11767 EPHB2: (EPHB2 OR EPTH3 OR ERK OR DRT OR HEK5) EPHRIN TYPE-B RECEPTOR C
118 CCNB2: (CCNB2) CYCLIN B2 G2/MITOTIC SPECIFIC CYCLIN B2. K
12085 SEMA4D: (SEMA4D OR CD100) SEMAPHORIN 4D PRECURSOR (LEUKOCYTE A C
12452 CD45_EX10-11: (PTPRC OR CD45) LEUKOCYTE COMMON ANTIGEN PRECURSOR A C J
12920 PRKCQ: (PRKCQ OR PRKCT) PROTEIN KINASE C, THETA TYPE (EC 2.7.1.—) (NPKC- K
14734 PRKCB_3: (PRKCB1 OR PRKCB OR PKCB) PROTEIN KINASE C, BETA TYPE (EC K
1497 PRKCB_1: (PRKCB1 OR PRKCB OR PKCB) PROTEIN KINASE C, BETA TYPE (EC K
1499 PRKCB_2: (PRKCB1 OR PRKCB OR PKCB) PROTEIN KINASE C, BETA TYPE (EC K
1507 PRKCH: (PRKCH OR PKCL) PROTEIN KINASE C, ETA TYPE (EC 2.7.1.—) (NPKC-ETA) K
17641 TNNC1: (TNNC1 OR TNNC) TROPONIN C, SLOW SKELETAL AND CARDIAC K
19690 RPLP0: (RPLP0) 60S ACIDIC RIBOSOMAL PROTEIN P0 (L10E). B D
20526 SEM2: (SEM2) SEMAPHORIN SEM2. C
211 CASP8_1: (MCH5 OR CASP8) CASPASE 8 PRECURSOR (EC 3.4.22.—) (ICE-LIKE B
22663 HNRPA1: (HNRPA1) HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN A1 B
22801 RPL6: (RPL6) 60S RIBOSOMAL PROTEIN L6 (TAX-RESPONSIVE ENHANCER B D
251 TNFRSF1B: (TNFRSF1B OR TNFR2 OR TNFBR OR TNFR-2) TUMOR NECROSIS A C
27255 RPS24: (RPS24 OR RPS19) 40S RIBOSOMAL PROTEIN S24 (S19). B D
28604 NPPA: (NPPA OR PND) ATRIAL NATRIURETIC FACTOR PRECURSOR (ANF) C
28658 RPL24: (RPL24) 60S RIBOSOMAL PROTEIN L24 (L30). B D
29221 NCAM2: (NCAM2 OR NCAM21) NEURAL CELL ADHESION MOLECULE 2 C
29909 IGHA1-IGHA2_M_HUMAN: (IGHA1) IG ALPHA-1 CHAIN C REGION (IGHA2) (IG C
30025 CD133: (PROM1 OR PROML1 OR PROM OR CD133 OR AC133) PROMININ 1 A C
303 ICAM2: (ICAM2 OR ICAM-2) INTERCELLULAR ADHESION MOLECULE-2 A C
30433 ITGAX: (ITGAX OR CD11C) INTEGRIN ALPHA-X PRECURSOR (LEUKOCYTE A C
31020 F11R: (F11R OR JAM1 OR JCAM) JUNCTIONAL ADHESION MOLECULE 1 C
31114 NOP5: (NOP5) NUCLEOLAR PROTEIN NOP5 (NUCLEOLAR PROTEIN 5) (NOP58) B
32034 TFRC_5PRIME: (TFRC) TRANSFERRIN RECEPTOR PROTEIN (TFR1) (TR) (TFR) A C
322 KIT: (KIT OR SL) MAST/STEM CELL GROWTH FACTOR RECEPTOR PRECURSOR A C J
32719 RPL4: (RPL4 OR RPL1) 60S RIBOSOMAL PROTEIN L4 (L1). B D
337 IL6R: (L6RA OR IL6R) INTERLEUKIN-6 RECEPTOR ALPHA CHAIN PRECURSOR A C
339 IL7R: (IL7R) INTERLEUKIN-7 RECEPTOR ALPHA CHAIN PRECURSOR (IL-7R- A C J
3454 ITGAM: (ITGAM OR CR3A OR CD11B) INTEGRIN ALPHA-M PRECURSOR (CELL A C J
349 FLT3: (FLT3 OR STK1 OR FLT-3 OR FLK-2) FL CYTOKINE RECEPTOR PRECURSOR A C
357 PDGFRB: (PDGFRB OR PDGFR) BETA PLATELET-DERIVED GROWTH FACTOR A C K
3929 RPSA: (RPSA OR LAMR1 OR LAMBR OR P40-8) 40S RIBOSOMAL PROTEIN SA (P40) B D
399 CD58_HUMAN: (CD58 OR LFA3) LYMPHOCYTE FUNCTION-ASSOCIATED A C
403 SELE: (SELE OR ELAM1 OR ELAM-1) E-SELECTIN PRECURSOR (ENDOTHELIAL A C
405 SELL: (SELL OR LYAM1 OR LNHR OR LY-22) L-SELECTIN PRECURSOR (LYMPH A C J
4068 NFKB1: (NFKB1) NUCLEAR FACTOR NF-KAPPA-B P105 SUBUNIT (DNA-BINDING K
416 CD68: (CD68) MACROSIALIN PRECURSOR (CD68 ANTIGEN) (GP110). A C
422 TFRC_MIDDLE: (TFRC) TRANSFERRIN RECEPTOR PROTEIN (TFR1) (TR) (TFR) A C
466 ITGAL: (ITGAL OR CD11A OR LFA-1) INTEGRIN ALPHA-L PRECURSOR A C
475 ITGB2: (ITGB2 OR CD18) INTEGRIN BETA-2 PRECURSOR (CELL SURFACE A C
489 CD24: (CD24 OR CD24A) SIGNAL TRANSDUCER CD24 PRECURSOR (M1/69-J11D A C J
4995 NRG3: (NRG3) PRO-NEUREGULIN-3 PRECURSOR (PRO-NRG3) [CONTAINS: C
501 PECAM1: (PECAM1 OR PECAM-1 OR PECAM) PLATELET ENDOTHELIAL CELL A C
505 CD33: (CD33) MYELOID CELL SURFACE ANTIGEN CD33 PRECURSOR (GP67) A C
506 CD34: (CD34) HEMATOPOIETIC PROGENITOR CELL ANTIGEN CD34 PRECURSOR. A C J
512 CD37: (CD37) LEUKOCYTE ANTIGEN CD37. A C
5131 CDK1: (CDC2) CELL DIVISION CONTROL PROTEIN 2 HOMOLOG (EC 2.7.1.—) (P34 K
514 CD38: (CD38) ADP-RIBOSYL CYCLASE 1 (EC 3.2.2.5) (CYCLIC ADP-RIBOSE A C K
526 ITGA2B: (ITGA2B OR ITGAB OR GP2B) PLATELET MEMBRANE GLYCOPROTEIN A C J
552 ITGA3: (ITGA3) INTEGRIN ALPHA-3 PRECURSOR (GALACTOPROTEIN B3) A C
554 ITGA4: (ITGA4 OR VLA-4) INTEGRIN ALPHA-4 PRECURSOR (INTEGRIN ALPHA- A C
558 ITGA6: (ITGA6) INTEGRIN ALPHA-6 PRECURSOR (VLA-6) (CD49F) (INTA6) A C
563 ICAM1: (ICAM1 OR ICAM-1) INTERCELLULAR ADHESION MOLECULE 1 A C
606 HTR4: (HTR4) 5-HYDROXYTRYPTAMINE 4 RECEPTOR (5-HT-4) (SEROTONIN K
632 CHRM1: (CHRM1) MUSCARINIC ACETYLCHOLINE RECEPTOR M1. K
7951 RPL7A: (RPL7A OR SURF3 OR SURF-3) 60S RIBOSOMAL PROTEIN L7A (SURFEIT B D
11701 CD44_EX16-20_HUMAN: (CD44 OR LHR) CD44 ANTIGEN PRECURSOR (PHAGOCYTIC A B C
11704 CD44_EX13-15_HUMAN: (CD44 OR LHR) CD44 ANTIGEN PRECURSOR (PHAGOCYTIC A B C
11707 CD44_EX3-5_HUMAN: (CD44 OR LHR) CD44 ANTIGEN PRECURSOR (PHAGOCYTIC A B C
12704 CD44_EX11-13_HUMAN: (CD44 OR LHR) CD44 ANTIGEN PRECURSOR (PHAGOCYTIC A B C
14752 VGR1: (FLT1 OR FLT OR FRT) VASCULAR ENDOTHELIAL GROWTH FACTOR C
2342 TACE: (ADAM17 OR TACE OR CSVP) ADAM 17 PRECURSOR (EC 3.4.24.—) (A A
332 IL3RA: ((IL3RAX OR IL3RA OR IL3R OR IL3RX) AND (IL3RAY OR IL3RA OR IL3R OR A
359 THBD: (THBD OR THRM) THROMBOMODULIN PRECURSOR (FETOMODULIN) (TM) A
399 CD58_HUMAN: (CD58 OR LFA3) LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN 3 A
416 CD68: (CD68) MACROSIALIN PRECURSOR (CD68 ANTIGEN) (GP110). A
438 KAI1: (KAI1 OR CD82 OR SAR2) CD82 ANTIGEN (INDUCIBLE MEMBRANE PROTEIN A
469 ANPEP: (ANPEP OR PEPN OR APN OR CD13 OR LAP1 OR LAP-1) AMINOPEPTIDASE N A
489 CD24: (CD24 OR CD24A) SIGNAL TRANSDUCER CD24 PRECURSOR (M1/69-J11D A B
5018 CTNNB1: (CTNNB1 OR CTNNB) BETA-CATENIN. C
506 CD34: (CD34) HEMATOPOIETIC PROGENITOR CELL ANTIGEN CD34 PRECURSOR. A B
538 CD44_EX10-12_HUMAN: (CD44 OR LHR) CD44 ANTIGEN PRECURSOR (PHAGOCYTIC A B C
543 CD47: (CD47 OR IAP) LEUKOCYTE SURFACE ANTIGEN CD47 PRECURSOR A
554 ITGA4: (ITGA4 OR VLA-4) INTEGRIN ALPHA-4 PRECURSOR (INTEGRIN ALPHA-IV) A
11804 GATA4_HUMAN: (GATA4) TRANSCRIPTION FACTOR GATA-4 (GATA BINDING A B C
12627 CRIP1: (CRIP1 OR CRIP) CYSTEINE-RICH PROTEIN 1 (CYSTEINE-RICH INTESTINAL B
13004 ELAVL2: (ELAVL2 OR HUB) ELAV-LIKE PROTEIN 2 (HU-ANTIGEN B) (HUB) (ELAV- C
13118 PMX2B: (PMX2B) PAIRED MESODERM HOMEOBOX PROTEIN 2B (PAIRED-LIKE A B C
15783 EN1: (EN1) HOMEOBOX PROTEIN ENGRAILED-1 (HU-EN-1). A B C
16116 NKX2-2: (NKX2-2 OR NKX2B OR NKX2.2) HOMEOBOX PROTEIN NKX-2.2 A B C
18160 HDAC2: (HDAC2) HISTONE DEACETYLASE 2 (HD2). A C
23248 SOX2: (SOX2) TRANSCRIPTION FACTOR SOX-2. A B C
30671 RARA1_HUMAN: (RARA OR NR1B1) RETINOIC ACID RECEPTOR ALPHA (RAR- A B C
30815 GATA5: (GATA5) TRANSCRIPTION FACTOR GATA-5 (GATA BINDING FACTOR-5). A B C
31002 DJ924G13.1: (DJ924G13.1 OR KIAA1221) DJ924G13.1 (KIAA1221) (PUTATIVE ZINC B
31153 SNAI1: (SNAI1 OR SNAH) ZINC FINGER PROTEIN SNAI1 (SNAIL PROTEIN B C
3535 JUN: (JUN) TRANSCRIPTION FACTOR AP-1 (ACTIVATOR PROTEIN 1) (AP1) (PROTO- A B C
3644 JUNB: (JUNB) TRANSCRIPTION FACTOR JUN-B (G0S3). A B C
4072 NFKB3: (RELA OR NFKB3) TRANSCRIPTION FACTOR P65 (NUCLEAR FACTOR NF- A B C
4197 HIF1A: (HIF1A) HYPOXIA-INDUCIBLE FACTOR 1 ALPHA (HIF-1 ALPHA) (ARNT A B C
4237 NEUROG1: (NEUROG1 OR NGN1 OR NGN OR NEUROD3 OR ATH4C) NEUROGENIN 1 A B C
4251 TAL1: (TAL1 OR SCL OR TCL5) T-CELL ACUTE LYMPHOCYTIC LEUKEMIA-1 B C
4257 TCF4: (TCF4 OR ITF2 OR SEF2) TRANSCRIPTION FACTOR 4 (IMMUNOGLOBULIN A B C
4275 EBCTF: (EBF) EARLY B-CELL TRANSCRIPTION FACTOR (FRAGMENT). (COE1 OR A B C
4289 HESR1: (HESR-1 OR CHF2 OR HEY1) HAIRY AND ENHANCER OF SPLIT RELATED-1 A B C
4418 MEF-2C: (MEF2C) MYOCYTE-SPECIFIC ENHANCER FACTOR 2C. A B C
4446 TBX3: (TBX3) T-BOX TRANSCRIPTION FACTOR TBX3 (T-BOX PROTEIN 3). A B C
4764 RARB2_1: (RARB OR NR1B2 OR HAP) RETINOIC ACID RECEPTOR BETA-2 (RAR- A B C
4767 SMAD3_HUMAN: (MADH3 OR SMAD3 OR MAD33) MOTHERS AGAINST A C
4913 RXRG: (RXRG OR NR2B3) RETINOIC ACID RECEPTOR RXR-GAMMA. A B C
5004 SMAD1: (MADH1 OR SMAD1 OR MADR1 OR BSP1) MOTHERS AGAINST A C
5016 ATM: (ATM) SERINE-PROTEIN KINASE ATM (EC 2.7.1.37) (ATAXIA C
91 P53: (TP53 OR P53) CELLULAR TUMOR ANTIGEN P53 (TUMOR SUPPRESSOR P53) A C
9663 HERMES: (HERMES OR RBPMS) RNA-BINDING PROTEIN WITH MULTIPLE C
CD PrepaCyte MNC CD133 MSC LinNeg
Example 13 Karyotypic Analysis of MLPC
US5744347 Apr 6, 1994 Apr 28, 1998 Ohio University Edison Biotechnology Institute Yolk sac stem cells and their uses
US5789147 Dec 5, 1994 Aug 4, 1998 New York Blood Center, Inc. Method for concentrating white cells from whole blood by adding a red cell sedimentation reagent to whole anticoagulated blood
US5965436 Nov 13, 1997 Oct 12, 1999 Osiris Therapeutics, Inc. Method of isolating mesenchymal stem cells associated with isolated megakaryocytes by isolating megakaryocytes
US6103530 Oct 23, 1998 Aug 15, 2000 Cytotherapeutics, Inc. Cultures of human CNS neural stem cells
US6140121 Oct 17, 1996 Oct 31, 2000 Advanced Reproduction Technologies, Inc. Methods and compositions to improve germ cell and embryo survival and function
US6436704 Apr 10, 2000 Aug 20, 2002 Raven Biotechnologies, Inc. Human pancreatic epithelial progenitor cells and methods of isolation and use thereof
US6477090 Aug 28, 2001 Nov 5, 2002 Hitachi, Ltd. Semiconductor device, microcomputer and flash memory
US6491917 Jul 30, 1999 Dec 10, 2002 Stemcell Technologies Inc. Antibody composition for debulking blood and bone marrow samples from CML patients
US6498034 Mar 26, 1999 Dec 24, 2002 Novartis Ag Method of producing dendritic cells
US6680198 Sep 20, 1999 Jan 20, 2004 The Children's Medical Center Corporation Engraftable human neural stem cells
US6946293 Aug 9, 2000 Sep 20, 2005 Es Cell International Pte Ltd. Progenitor cells, methods and uses related thereto
US6962698 Aug 17, 1999 Nov 8, 2005 Gamida Cell Ltd. Methods of controlling proliferation and differentiation of stem and progenitor cells
US6967086 Mar 28, 2002 Nov 22, 2005 Becton Dickinson And Company Method for determining the presence or absence of respiring cells on a three-dimensional scaffold
US6986887 Jun 28, 2002 Jan 17, 2006 Morphogenesis, Inc. Universal stem cells
US20010034061 Jan 31, 2001 Oct 25, 2001 California Institute Of Technology Methods for isolation and activation of, and control of differentiation from, stem and progenitor cells
US20010046489 Dec 6, 2000 Nov 29, 2001 Habener Joel E. Stem cells of the islets of langerhans and their use in treating diabetes mellitus
US20020012903 Dec 22, 2000 Jan 31, 2002 Goldman Steven A. Method for isolating and purifying multipotential neural progenitor cells and multipotential neural progenitor cells
US20020045196 May 12, 2000 Apr 18, 2002 Walt Mahoney Methods of isolating trophoblast cells from maternal blood
US20020064519 Jan 14, 2002 May 30, 2002 Bruder Scott P. Uses for non-autologous mesenchymal stem cells
US20020068045 Mar 14, 2001 Jun 6, 2002 Reubinoff Benjamin Eithan Embryonic stem cells and neural progenitor cells derived therefrom
US20020132987 Sep 25, 1996 Sep 19, 2002 David J. Anderson Methods and compositions for neural progenitor cells
US20020164308 Oct 4, 2001 Nov 7, 2002 Reubinoff Benjamin Eithan Embryonic stem cells and neural progenitor cells derived therefrom
US20020164790 Dec 7, 2000 Nov 7, 2002 David Warburton Lung stem cells and lung regeneration
US20020168763 Nov 30, 2001 Nov 14, 2002 Yan Wen Liang Isolated homozygous stem cells, differentiated cells derived therefrom, and materials and methods for making and using same
US20020177227 Sep 24, 2001 Nov 28, 2002 Morey Kraus Modulation of primary stem cell differentiation
US20020192816 Apr 9, 2002 Dec 19, 2002 Roberts Penelope E. Human pancreatic epithelial progenitor cells and methods of isolation and use thereof
US20030027233 Mar 7, 2002 Feb 6, 2003 Collins Daniel P. Cell separation compositions and methods
US20030092078 Jul 12, 2002 May 15, 2003 Stemcell Technologies Inc. Method for separating cells using immunorosettes
US20030113910 Dec 18, 2001 Jun 19, 2003 Mike Levanduski Pluripotent stem cells derived without the use of embryos or fetal tissue
US20030157078 Mar 31, 2003 Aug 21, 2003 University Of Southern California, A California Corporation Identification of a pluripotent pre-mesenchymal, pre-hematopoietic progenitor cell
US20030161818 Feb 25, 2002 Aug 28, 2003 Kansas State University Research Foundation Cultures, products and methods using stem cells
US20030165852 Nov 15, 2001 Sep 4, 2003 Schueler Paula A. Methods and reagents for identifying rare fetal cells in the maternal circulation
US20030235563 * Apr 21, 2003 Dec 25, 2003 Strom Stephen C. Placental derived stem cells and uses thereof
US20040018621 Mar 14, 2003 Jan 29, 2004 Lola Reid Primitive and proximal hepatic stem cells
US20040058398 Sep 26, 2003 Mar 25, 2004 Nora Sarvetnick Pancreatic progenitor cells and methods for isolating the same
US20040058412 Sep 20, 2002 Mar 25, 2004 Neuronyx, Inc. Cell populations which co-express CD49c and CD90
US20040137612 Apr 23, 2002 Jul 15, 2004 Dolores Baksh Progenitor cell populations , expansions thereof, and growth of non-hematopoietic cell types and tissues therefrom
US20040142463 Nov 4, 2003 Jul 22, 2004 George Walker Methods, compositions, and automated systems for separating rare cells from fluid samples
1 Abe et al., "Cells Derived from the Circulation Contribute to the Repair of Lung Injury," Am. J. Respir. Crit. Care Med., 2004, 170(11):1158-1163.
2 Authorized Officer Beate Giffo-Schmitt, International Preliminary Report on Patentability, PCT/US06/33129, mailed Mar. 6, 2008, 8 pages.
3 Authorized Officer Jung Hee Han, International Search Report/Written Opinion, PCT/US2008/71207, mailed Jul. 25, 2008, 10 pages.
4 Authorized Officer Michael A. Belyavski, International Search Report/Written Opinion, PCT/US05/13244, mailed Dec. 12, 2006, 7 pages.
5 Authorized Officer Philippe Becamel, International Preliminary Report on Patentability, PCT/US07/66797, mailed Oct. 30, 2008, 6 pages.
6 Authorized Officer Q. Janice Li, International Search Report/Written Opinion, PCT/US07/66797, mailed Sep. 23, 2008, 9 pages.
7 Authorized Officer Yoshiko Kuwahara, International Preliminary Report on Patentability, PCT/US05/13244, mailed Jan. 11, 2007, 5 pages.
8 Baksh et al., "Adult mesenchymal stem cells: characterization, differentiation, and application in cell and gene therapy," J. Cell. Mol. Med., 2004, 8(3):301-316.
9 BDTM Biosciences Technical Bulletin BDTM Three Dimensional Collagen Composite and OPLA Scaffolds, 2002.
10 Belov et al., "Immunophenotyping of leukemias using a cluster of differentiation antibody microarray," Cancer Res., 2001, 61(11):4483-4489.
11 * Belov et al., Immunophenotyping of leukemias using a cluster of differentiation antibody microarray Cancer Res. Jun. 1, 2001;61(11):4483-9.
12 Bensidhoum et al., "Homing of in vitro expanded Stro-1- or Stro-1+ human mesenchymal stem cells into the NOD/SCID mouse and their role in supporting human CD34 cell engraftment," Blood, 2004, 103:3313-3319.
13 Berger et al., "Differentiation of umbilical cord blood-derived multilineage progenitor cells into respiratory epithelial cells," Cytotherapy, 2006, 8(5):480-487.
14 Bigbee et al., "Monoclonal antibodies specific for the M- and N-forms of human glycophorin A," Mol. Immunol., 1983, 20(12):1353-1362.
15 Bradley, "Modifying the mammalian genome by gene targeting," Curr. Opin. Biotechnol., 1991, 2:823-829.
16 Cadet et al., "A Functionally Coupled mu3-Like Opiate Receptor/Nitric Oxide Regulatory Pathway in Human Multi-Lineage Progenitor Cells," J. Immunol., 2007, 179:5839-5844.
17 Choi et al., "Chondrogenic differentiation of human umbilical cord blood-derived multilineage progenitor cells in atelocollagen," Cytotherapy, 2008, 0:1-9.
18 Cole et al., "The EBV-Hybridoma Technique and its Application to Human Lung Cancer" Monoclonal Antibodies and Cancer Therapy, 1985, pp. 77-96.
19 Cote et al., "Generation of human monoclonal antibodies reactive with cellular antigens." Proc. Natl. Acad. Sci. USA, 1983, 80:2026-2030.
20 D'Ippolito et al., "Marrow-isolated adult multilineage inducible (MIAMI) cells, a unique population of postnatal young and old human cells with extensive expansion and differentiation potential," J. Cell Sci., 2004, 117:2971-2981.
21 Eggens et al., "Specific Interaction between Lex and Lex Determinants. A Possible Basis for Cell Recognition in Preimplantation Embryos and in Embryonal Carcinoma Cells," J. Biol. Chem., 1989, 264(16):9476-9484.
22 Erices et al., "Mesenchymal progenitor cells in human umbilical cord blood," Br. J. Haematol., 2000, 109:235-242.
23 Examiner Christine Hall, Examination Report, Australian Application No. 2005241008, mailed Mar. 25, 2009, 5 pages.
24 Examiner Donata Paresce, Communication pursuant to Article 94(3) EPC, EP Application No. 05 736 785, mailed Jul. 22, 2009, 4 pages.
25 Examiner Donata Paresce, Examination Report, EP Application No. 05 73 6785, mailed Mar. 3, 2008, 6 pages.
26 Examiner Donata Paresce, Supplementary European Search Report, EP Application No. 05 73 6785, mailed Nov. 28, 2007, 6 pages.
27 Examiner Fereydoun Ghotb Sajjadi, Office Action, U.S. Appl. No. 11/452,502, mailed Jan. 14, 2009, 13 pages.
28 Examiner Fereydoun Ghotb Sajjadi, Office Action, U.S. Appl. No. 11/452,502, mailed Jul. 31, 2008, 12 pages.
29 Examiner Maria Gomez Leavitt, Office Action, U.S. Appl. No. 11/110,299, mailed Apr. 1, 2009, 9 pages.
30 Examiner Maria Gomez Leavitt, Office Action, U.S. Appl. No. 11/110,299, mailed Apr. 29, 2008, 14 pages.
31 Examiner Maria Gomez Leavitt, Office Action, U.S. Appl. No. 11/110,299, mailed Oct. 27, 2008, 13 pages.
32 Examiner Qian Janice Li, Office Action, U.S. Appl. No. 11/736,273, mailed Apr. 28, 2009, 12 pages.
33 Forraz et al., "AC133+ umbilical cord blood progenitors demonstrate rapid self-renewal and low apoptosis," British Journal of Haematology, 2002, 119:516-524.
34 Forraz et al., "Characterization of a lineage-negative stem-progenitor cell population optimized for ex vivo expansion and enriched for LTC-IC," Stem Cells, 2004, 22:100-108.
35 Forraz et al., "Haemopoietic and neuroglial progenitors are promoted during cord blood ex vivo expansion," British Journal of Haematology, 2002, 119:888.
36 Fowler and Greenspan, "Application of Nile Red, a Fluorescent Hydrophobic Probe, for the Detection of Neutral Lipid Deposits in Tissue Sections: Comparison with Oil Red O," J. Histochem. Cytochem., 1985, 33(8):833-836.
37 Goodwin et al., "Multilineage Differentiation Activity by Cells Isolated from Umbilical Cord Blood: Expression of Bone, Fat, and Neural Markers," Biol. Blood Marrow Transplant., 2001, 7:581-588.
38 Hou et al., "Study of in vitro expansion and differentiation into neuron-like cells of human umbilical cord blood mesenchymal stem cells," Chin. J. Hematol., 2002, 23(8):414-419 (English Abstract only).
39 International Search Report/Written Opinion mailed Apr. 27, 2007 in PCT/US06/33129, 9 pages.
40 International Search Report/Written Opinion mailed Dec. 12, 2006 in PCT/US2005/13244, 7 pages.
41 Jäger and Krauspe, "Antigen expression of cord blood derived stem cells under osteogenic stimulation in vitro," Cell Biology International, 2007, 31:950-957.
42 Jaiswal et al., "Osteogenic Differentiation of Purified, Culture-Expanded Human Mesenchymal Stem Cells In Vitro," J. Cell. Biochem., 1997, 64:295-312.
43 Jennings et al., "CD9 cluster workshop report: cell surface binding and functional analysis," Leucocyte Typing V, 1995, Schlossmann et al. (eds.), Oxford University Press, Oxford, pp. 1249-1251.
44 Jiang et al., "Pluripotency of mesenchymal stem cells derived from adult marrow," Nature, 2002, 418:41-49.
45 Johnson et al., "Bone marrow may be source of new egg-cell generation in adult mammals," [online] 2005, [retrieved on Jul. 29, 2005]. Retrieved from the Internet: - releases/2005-07/mgh-bmm071505.php>, 3 pages.
46 Jones et al., "Isolation and Characterization of Bone Marrow Multipotential Mesenchymal Progenitor Cells," Arth. Rheum., 2002, 46(12):3349-3360.
47 Kannagi et al., "A Series of Human Erythrocyte Glycosphingolipids Reacting to the Monoclonal Antibody Directed to a Developmentally Regulated Antigen, SSEA-1," J. Biol. Chem., 1982, 257(24):14865-14874.
48 Kay et al., "Gene therapy," Proc. Natl. Acad. Sci. USA, 1997,94:12744-12746.
49 Kern et al., "Comparative Analysis of Mesenchymal Stem Cells from Bone Marrow, Umbilical Cord Blood, or Adipose Tissue," Stem Cells, 2006, 24:1294-1301.
50 Kobune et al., "Telomerized human multipotent mesenchymal cells can differentiate into hematopoietic and cobblestone area-supporting cells," Exp. Hematol., 2003, 31:715-722.
51 Kögler et al., "A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential," J. Exp. Med., 2004, 200(2):123-135.
52 Kögler et al., "Cytokine production and hematopoiesis supporting activity of cord blood-derived unrestricted somatic stem cells," Exp. Hematol., 2005, 33:573-583.
53 Krause et al., "Multi-Organ, Multi-Lineage Engraftment by a Single Bone Marrow-Derived Stem Cell," Cell, 2001, 105:369-377.
54 Lakshmipathy et al., "Efficient Transfection of Embryonic and Adult Stem Cells," Stem Cells, 2004, 22:531-543.
55 Lam et al., "Preclinical ex vivo expansion of cord blood hematopoietic stem and progenitor cells: duration of culture; the media, serum supplements, and growth factors used; and engraftment in NOD/SCID mice," Transfusion, 2001, 41:1567-1576.
56 Lanza et al., "cDNA cloning and expression of platelet p24/CD9. Evidence for a new family of multiple membrane-spanning proteins," J. Biol. Chem., 1991, 266(16):10638-10645.
57 Lechner et al., "Clonal growth of epithelial cells from normal adult human bronchus," Cancer Res., 1981, 41:2294-2304.
58 Lee et al., "Isolation of multipotent mesenchymal stem cells from umbilical cord blood," Blood, 2004, 103(5):1669-1675.
59 Lodie et al., "Systematic analysis of reportedly distinct populations of multipotent bone marrow-derived stem cells reveals a lack of distinction," Tissue Eng., 2002, 8(5):739-751.
60 Madlambayan et al., "Controlling Culture Dynamics for the Expansion of Hematopoietic Stem Cells," J. Hematother. Stem Cell Res., 2001, 10(4):481-492.
61 * Madlambayan GJ, Rogers I, Casper RF, Zandstra PW. Controlling culture dynamics for the expansion of hematopoietic stem cells. J Hematother Stem Cell Res. Aug. 2001;10(4):481-92.
62 Magnani et al., "Monoclonal Antibodies PMN 6, PMN 29, and PM-81 Bind Differently to Glycolipids Containing a Sugar Sequence Occurring in Lacto-N-Fucopentaose III," Arch. Biochem. Biophys., 1984, 233(2):501-506.
63 McGuckin et al., "Colocalization analysis of sialomucins CD34 and CD164," Stem Cells, 2003, 21:162-170.
64 McGuckin et al., "Multiparametric analysis of immature cell populations in umbilical cord blood and bone marrow," Eur. J. Haematol., 2003, 71:341-350.
65 McGuckin et al., "Production of stem cells with embryonic characteristics from human umbilical cord blood," Cell Prolif., 2005, 38:245-255.
66 McGuckin et al., "Thrombopoietin, flt3-ligand and c-kit-ligand modulate HOX gene expression in expanding cord blood CD133+ cells," Cell Prolif., 2004, 37:295-306.
67 McGuckin et al., "Umbilical cord blood stem cells can expand hematopoietic and neuroglial progenitors in vitro," Experimental Cell Research, 2004, 295:350-359.
68 Meng et al., "Endometrial regenerative cells: A novel stem cell population," J. Translational Med., 2007, 5:57.
69 Outram et al., "Erythromyeloid Lineage Fidelity is Conserved in Erythroleukaemia," Leukemia Research, 1988, 12(8):651-657.
70 Perez et al., "Human Cord Blood derived Stem Cells Differentiated into Hormone-Expressing Islet Cell-like Aggregates to Produce Insulin as an Alternative to Pancreatic transplant for diabetic and pancreatic Cancer Patients," http://www.eliondiagnostics.com/pdf/news/Celprogen-Stem-Cell-Abstract.pdf#search=%22perez% 20pancreatic%20cord%20blood%22, Stem Cells Research and Therapeutics Conference, San Diego, CA, Apr. 11-12, 2005, 4 pages.
71 Phinney and Prockop, "Concise Review: Mesenchymal Stem/Multipotent Stromal Cells: The State of Transdifferentiation and Modes of Tissue Repair-Current Views," Stem Cells, 2007, 25:2896-2902.
72 Pittenger et al. "Adult Mesenchymal Stem Cells: Potential for Muscle and Tendon Regeneration and use in Gene Therapy." Journal of Musculoskeletal Interactions. 2002, 2 (4) 309-320.
73 Pittenger et al., "Multilineage Potential of Adult Human Mesenchymal Stem Cells," Science, 1999, 284:143-147.
74 Reinberg, "Banking on Stem Cells," [online]. The Scientist, 2005, [retrieved on Jul. 28, 2005]. Retrieved from the Internet: , 5 pages.
75 Rosada et al. "The human umbilical cord blood: A potential source for osteoblast progenitor cells." Calcified Tissue International. 2003, 72 (2) 135-142.
76 Rubinstein et al., "Anti-Platelet Antibody Interactions with Fcgamma Receptor," Semin. Thromb Hemost., 1995, 21(1):10-22.
77 Rutella et al., "Identification of a Novel Subpopulation of Human Cord Blood CD34-CD133-CD7-CD45+Lineage- Cells Capable of Lymphoid/NK Cell Differentiation After In Vitro Exposure to IL-15," J. Immunol., 2003, 171:2977-2988.
78 Sakaguchi et al., "Comparison of Human Stem Cells Derived from Various Mesenchymal Tissues," Arth. Rheum., 2005, 52(8):2521-2529.
79 Simonsen et al., "Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells," Nat. Biotechnol., 2002, 20:592-596.
80 Solter and Knowles, "Monoclonal antibody defining a stage-specific mouse embryonic antigen (SSEA-1)," Proc. Natl. Acad. Sci. USA, 1978, 75(11):5565-5569.
81 Stefano et al., "Endogenous morphine/nitric oxide-coupled regulation of cellular physiology and gene expression: Implications for cancer biology," Semin. Cancer Biol., 2008, 18(3):199-210.
82 Supplementary Search Report mailed Nov. 28, 2007 in EP 05 73 6785, 6 pages.
83 Telen and Bolk, "Human red cell antigens. IV. The abnormal sialoglycoprotein of Gerbich-negative red cells," Transfusion, 1987, 27(4):309-3l4.
84 Terai et al., "Immortalization of Human Fetal Cells: The Life Span of Umbilical Cord Blood-derived Cells Can Be Prolonged without Manipulating p16INK4a/RB Braking Pathway," Mol. Biol. Cell, 2005, 16:1491-1499.
85 The Patent Office of the State Intellectual Property Office of the People's Republic of China, Examination Report, Chinese Application No. 200580012739.3, mailed Mar. 9, 2009, 10 pages.
86 Tocci and Forte, "Mesenchymal stem cell: use and perspectives," Hematol. J., 2003, 4(2):92-96.
87 Von dem Borne and Modderman, "P2.1 Cluster Report: CD9" Leucocyte Typing IV, 1989, Knapp et al. (eds.), Oxford University Press, Oxford, pp. 989-992.
88 Wagner et al., "Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood," Exp. Hematol., 2005, 33:1402-1416.
89 Whiting et al., "Three-dimensional analysis of CD34 sialomucin distribution on cord blood and bone marrow," British Journal of Haematology, 2003, 122:771-777.
90 Wright and Tomlinson, "The ins and outs of the transmembrane 4 superfamily," Immunology Today, 1994, 15(12):588-594.
91 Xiao et al., "Transplantation of a novel cell line population of umbilical cord blood stem cells ameliorates neurological deficits associated with ischemic brain injury," Stem Cells and Development, 2005, 14:722-733.
92 Yoon et al., "Clonally expanded novel multipotent stem cells from human bone marrow regenerate myocardium after myocardial infarction," J. Clin. Invest., 2005, 115:326-338.
US8172784 Oct 11, 2007 May 8, 2012 The General Hospital Corporation Compositions, methods, and devices for treating liver disease
US20080145442 * Oct 11, 2007 Jun 19, 2008 Yarmush Martin L Compositions, Methods, and Devices for Treating Liver Disease
U.S. Classification 424/93.1, 424/93.71, 435/7.23, 435/355, 435/325, 435/2, 435/7.25, 436/523, 435/7.24
International Classification A01N63/00, C12Q1/37, C12N5/00, A61K8/18, A01N1/02, C12N5/074
Cooperative Classification C12N5/0607, C12N2506/03
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:COLLINS, DANIEL P.;SPRAGUE, STACEY L.;TIGGES, BARBARA M.;REEL/FRAME:016984/0336